Kairos Pharma Ltd. (NYSE American: KAPA) will take a prominent role at the 24th Annual Discovery on Target Drug Discovery Conference, scheduled for September 28 to October 1 in Boston, where President and Chief Scientific Officer Neil Bhowmick will present and moderate discussions on the company's approach to combating cancer drug resistance. The conference, a key gathering for the drug discovery community, provides a platform for Kairos to showcase its scientific strategy and potentially attract partnerships or investor interest.
Bhowmick will moderate a breakout session on September 30 titled "Winning the Race against Cancer Therapy Resistance," which will focus on Kairos' strategy of targeting cancer drug resistance to extend the efficacy of previously effective drug candidates. He will also deliver an oral plenary presentation on September 30 at 2:35 p.m. Eastern on KROS-101, the company's drug candidate targeting solid tumors. The presentation will center on KROS-101's targeting of GITR (Glucocorticoid-Induced TNF Receptor) to increase T-cell function and expand effector T-cells with anti-tumor activity. This mechanism could offer a new avenue for patients whose cancers have become resistant to standard therapies.
The importance of this announcement lies in its potential to validate Kairos' scientific approach and raise its profile among researchers, clinicians, and investors. By presenting at a prestigious conference, Kairos can demonstrate the credibility of its pipeline, which is built on structural biology to overcome drug resistance and immune suppression in cancer. The company's lead candidate, ENV-105, is an antibody that targets CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. The addition of KROS-101 to the pipeline underscores Kairos' commitment to addressing therapy resistance from multiple angles.
For investors, the presentation could serve as a catalyst for the stock, as it provides an opportunity for the company to communicate its progress and differentiation in a crowded oncology space. The latest news and updates relating to KAPA are available in the company's newsroom at https://nnw.fm/KAPA. To view the full press release, visit https://nnw.fm/DoHxL. More information about Kairos Pharma can be found at Kairos Pharma (NYSE American: KAPA).
NetworkNewsWire, a specialized communications platform with a focus on financial news and content distribution, is one of 75+ brands within the Dynamic Brand Portfolio at IBN. The platform delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, and enhanced press release enhancement to ensure maximum impact. For more information, please visit NetworkNewsWire. Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer.
